Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial - InvestingNews.com
Mavacamten is a first-in-class, investigational cardiac myosin inhibitor being developed by Bristol Myers Squibb Study met all primary and secondary endpoints and patients receiving mavacamten demonstrated improvement in key cardiac measures after 16 we…
Mavacamten is a first-in-class, investigational cardiac myosin inhibitor being developed by Bristol Myers Squibb
Study met all primary and secondary endpoints and patients receiving mavacamten dem… [+13389 chars]
Read More
Other Stories in Health
- Dosa saree, Idli shirt and a pani puri watch? AI turns desi food into fashion
- Where and why men die younger: global data breaks it down
- 8 Best Foldable Rowing Machines, According to Editors and Certified Trainers
- Strawberry Lemon Cream Crepes {Grain-Free Options Included}
- What predicts belief in the afterlife? A massive global study has answers
- Getting active in midlife may boost brain resilience to Alzheimer’s
- May 2025 Cooking Challenge
- May 2025 Cooking Challenge
- TDP-43 dysfunction in brain blood vessels may drive Alzheimer's and ALS progression
.png)
